Log In
BCIQ
Print this Print this
 

MOR209/ES414 (formerly ES414)

  Manage Alerts
Collapse Summary General Information
Company Aptevo Therapeutics Inc.
DescriptionBispecific ADAPTIR molecule targeting prostate-specific membrane antigen (PSMA; FOLH1; GCPII) and CD3
Molecular Target Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) ; CD3
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation
PartnerMorphoSys AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$183.0M

$20.0M

$163.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/06/2015

Undisclosed

Undisclosed

Undisclosed

08/19/2014

$183.0M

$20.0M

$163.0M

Get a free BioCentury trial today